Table 1.
Prognostic impact of AF in HF: summary of randomised trials.
| Deaths, n (%) | p-value | |||||||
|---|---|---|---|---|---|---|---|---|
| Author | Setting | n | LVEF | Mean follow-up, years | %AF | SR | AF | |
| Carson et al | V-HEFT I&II | 1,427 | <45% | 2.5 | 19 | 480/1,221 (39) | 75/206 (36) | NS |
| Dries et al | SOLVD | 6,517 | <35% | 2.8 | 6 | 1,395/8,098 (23) | 149/419 (34) | <0.0001 |
| Mathew et al | DIG | 7,788 | All | 3.1 | 11 | 2,231/6,922 (32) | 375/866 (43) | <0.0001 |
| Crijns et al | PRIME II | 409 | <35% | 3.4 | 21 | 153/325 (47) | 50/84 (60) | <0.05 |
| Swedberg et al | COMET | 3,029 | <35% | 4.8 | 20 | 874/2,429 (36) | 258/600 (43) | <0.0005 |
| Olsson et al | CHARM | 7,601 | All | 3.1 | 15 | 1466/6,451 (23) | 365/1,148 (32) | <0.001 |
| Pederson et al | DIAMOND | 3,587 | <35% | N/A | 24 | 1951/2,661 (73) | 634/818 (77) | <0.001 |
AF = atrial fibrillation; LVEF: left ventricular ejection fraction; NS = not significant; N/A = not available; SR = sinus rhythm. Adapted with permission from Khan et al.7